NASDAQ:MACK Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free MACK Stock Alerts $14.68 0.00 (0.00%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$14.67▼$14.7150-Day Range$13.80▼$15.0052-Week Range$11.53▼$15.89Volume113,575 shsAverage Volume119,209 shsMarket Capitalization$213.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Merrimack Pharmaceuticals alerts: Email Address Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Merrimack Pharmaceuticals Stock (NASDAQ:MACK)Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Read More MACK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MACK Stock News HeadlinesApril 13, 2024 | americanbankingnews.comMerrimack Pharmaceuticals (NASDAQ:MACK) and Seelos Therapeutics (NASDAQ:SEEL) Critical ComparisonApril 3, 2024 | finance.yahoo.comDiagonal starts up with $128M to make better ‘activator’ antibody drugsApril 19, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 27, 2024 | businesswire.comMerrimack Receives $225 Million Milestone Payment from IpsenMarch 8, 2024 | msn.comStocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate CutsMarch 8, 2024 | investorplace.comMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023March 7, 2024 | businesswire.comMerrimack Reports Full Year 2023 Financial ResultsMarch 4, 2024 | finance.yahoo.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the companyApril 19, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.February 22, 2024 | benzinga.comMerrimack Pharmaceuticals Stock (NASDAQ:MACK), Analyst Ratings, Price Targets, PredictionsFebruary 17, 2024 | finance.yahoo.comMACK Mar 2024 14.000 putFebruary 17, 2024 | finance.yahoo.comMACK Mar 2024 4.000 putFebruary 15, 2024 | markets.businessinsider.comOnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical OfficerFebruary 14, 2024 | finance.yahoo.comMACK Feb 2024 16.000 putFebruary 14, 2024 | finance.yahoo.comIpsen drug approved by FDA for early pancreatic cancerFebruary 13, 2024 | msn.comThe S&P 500, Dow, Nasdaq are down as traders push back forecasts for interest rate cutsFebruary 13, 2024 | marketwatch.comMerrimack Pharmaceuticals to Hold Meeting on Corporate DissolutionFebruary 13, 2024 | finance.yahoo.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)February 13, 2024 | businesswire.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)December 12, 2023 | msn.com$2M Bet On Ford? Check Out These 4 Stocks Insiders Are BuyingDecember 10, 2023 | finance.yahoo.comWe're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To GrowNovember 10, 2023 | morningstar.comMerrimack Pharmaceuticals Inc MACKNovember 2, 2023 | finance.yahoo.comMerrimack Reports Third Quarter 2023 Financial ResultsOctober 24, 2023 | stockhouse.comOnconova Expands Leadership Team with Two Key AppointmentsOctober 20, 2023 | theglobeandmail.comThe Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC FirmAugust 15, 2023 | finance.yahoo.comWestern Standard LLC Boosts Stake in Merrimack Pharmaceuticals IncAugust 13, 2023 | insidermonkey.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call TranscriptSee More Headlines Receive MACK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/18/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MACK CUSIP59032810 CIK1274792 Webwww.merrimackpharma.com Phone617-720-8606Fax617-491-1386Employees426Year Founded2000Profitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-6.24% Return on Assets-6.09% Debt Debt-to-Equity RatioN/A Current Ratio43.50 Quick Ratio43.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book11.21Miscellaneous Outstanding Shares14,530,000Free Float10,337,000Market Cap$213.30 million OptionableOptionable Beta1.43 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Gary L. Crocker M.B.A. (Age 72)President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman Comp: $76kDr. Ulrik B. Nielsen Ph.D. (Age 52)Co-Founder & Independent Director Comp: $72.5kDr. Anthony J. Sinskey Ph.D. (Age 84)Sc.D., Co-Founder and Scientific Advisor Comp: $4.25kMr. Timothy R. Surgenor (Age 64)Secretary Key CompetitorsAcrivon TherapeuticsNASDAQ:ACRVImmutepNASDAQ:IMMPTheseus PharmaceuticalsNASDAQ:THRXProQR TherapeuticsNASDAQ:PRQRNGM BiopharmaceuticalsNASDAQ:NGMView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 8,610 shares on 3/11/2024Ownership: 4.194%Vanguard Group Inc.Bought 8,610 shares on 2/15/2024Ownership: 4.252%Barclays PLCBought 12,535 shares on 2/15/2024Ownership: 0.100%Citadel Advisors LLCBought 1,600 shares on 2/15/2024Ownership: 0.000%ADAR1 Capital Management LLCBought 549,418 shares on 2/14/2024Ownership: 3.837%View All Insider TransactionsView All Institutional Transactions MACK Stock Analysis - Frequently Asked Questions How have MACK shares performed in 2024? Merrimack Pharmaceuticals' stock was trading at $13.41 on January 1st, 2024. Since then, MACK shares have increased by 9.5% and is now trading at $14.68. View the best growth stocks for 2024 here. When is Merrimack Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our MACK earnings forecast. How were Merrimack Pharmaceuticals' earnings last quarter? Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced its earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter. When did Merrimack Pharmaceuticals' stock split? Merrimack Pharmaceuticals shares reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Merrimack Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM). How do I buy shares of Merrimack Pharmaceuticals? Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MACK) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIThe “Perfect Storm” for GoldGold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceUrgent alert: open this for a huge profit potentialTimothy SykesHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merrimack Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.